Psoriasis - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Psoriasis - Pipeline Review, H2 2018’, provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psoriasis

- The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects

- The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Psoriasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Psoriasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

Abeome Corp

AbGenomics International Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Affibody AB

Alfacyte Ltd

Allergan Plc

Almirall SA

Alteogen Inc ...

3SBio Inc

AbbVie Inc

Abeome Corp

AbGenomics International Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Affibody AB

Alfacyte Ltd

Allergan Plc

Almirall SA

Alteogen Inc

Alvotech Iceland

Amgen Inc

AnaptysBio Inc

ApoPharma Inc

Aptevo Therapeutics Inc

Arbor Pharmaceuticals LLC

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Athenex Inc

Atlantic Bio Sci LLC

Aurigene Discovery Technologies Ltd

Baliopharm AG

Bausch Health Companies Inc

Bayer AG

Beta Pharma Inc

BioApex sro

Biocad

Biocon Ltd

BioLingus AG

Bionovis SA

BirchBioMed Inc

Boehringer Ingelheim GmbH

Boston Pharmaceuticals Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

C4X Discovery Holdings PLC

CalciMedica Inc

Can-Fite BioPharma Ltd

Celgene Corp

Celon Pharma SA

ChemoCentryx Inc

ChironWells GmbH

Coherus BioSciences Inc

Compugen Ltd

Concenter BioPharma Silkim Ltd

Crescita Therapeutics Inc

Daiichi Sankyo Co Ltd

Dr. August Wolff GmbH & Co KG Arzneimittel

DURECT Corp

Eli Lilly and Co

ELORAC Inc

Escalier Biosciences BV

Evelo Biosciences Inc

Exicure Inc

Fresenius SE & Co KGaA

FunPep Co Ltd

FYB202 GmbH & Co KG

Galapagos NV

Galderma SA

Galectin Therapeutics Inc

Genentech Inc

GeneScience Pharmaceuticals Co Ltd

Genfit SA

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

GlycoMar Ltd

Grunenthal GmbH

Helix BioMedix Inc

HitGen LTD

Huabo Biopharm Co Ltd

Hualan Biological Engineering Inc

Hydra Biosciences Inc

iCo Therapeutics Inc

Immune Pharmaceuticals Inc

Immungenetics AG

Immunwork Inc

Innovation Pharmaceuticals Inc

Inspyr Therapeutics Inc

Instituto Biomar SA

Istesso Ltd

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Kadmon Corp LLC

Kaken Pharmaceutical Co Ltd

Kang Stem Biotech Co Ltd

Kv1.3 Therapeutics

Kymab Ltd

Lead Pharma Holding BV

LEO Pharma A/S

Link Health Group

Lupin Ltd

Lycera Corp

mAbxience SA

Maruho Co Ltd

Merck KGaA

Metrion Biosciences Ltd

MetrioPharm AG

Mitsubishi Tanabe Pharma Corp

Momenta Pharmaceuticals Inc

Mycenax Biotech Inc

Nanology LLC

Nichi-Iko Pharmaceutical Co Ltd

Nimbus Therapeutics LLC

Nordic Group BV

NovaLead Pharma Pvt Ltd

Novan Inc

Novartis AG

Nuevolution AB

Numab Innovation AG

Oncobiologics Inc

Orphagen Pharmaceuticals Inc

Pfizer Inc

Pharmedartis GmbH

Phenex Pharmaceuticals AG

Philogen SpA

PinCell srl

Pivot Pharmaceuticals Inc

Plant Advanced Technologies SA

Principia Biopharma Inc

Provectus Biopharmaceuticals Inc

Qilu Pharmaceutical Co Ltd

Realm Therapeutics Plc

Reata Pharmaceuticals Inc

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Samumed LLC

Sandoz International GmbH

Sareum Holdings Plc

SBI Biotech Co Ltd

selectION Inc

Shanghai Henlius Biotech Co Ltd

Shulov Innovative Science Ltd

Sienna Biopharmaceuticals Inc

Soligenix Inc

Spherium Biomed SL

sterna biologicals GmbH & Co KG

Sublimity Therapeutics Ltd

Sun Pharma Advanced Research Company Ltd

Syntrix Biosystems Inc

Tasly Pharmaceutical Group Co Ltd

TheraMAB LLC

Tolero Pharmaceuticals Inc

Torrent Pharmaceuticals Ltd

UCB SA

Vicore Pharma AB

Visionary Pharmaceuticals Inc

vTv Therapeutics Inc

Wellstat Therapeutics Corp

XBiotech Inc

Yuhan Corp

Zai Lab Ltd

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Psoriasis – Overview 9

Psoriasis – Therapeutics Development 10

Psoriasis – Therapeutics Assessment 42

Psoriasis – ...

Table of Contents

Table of Contents 2

Introduction 8

Psoriasis – Overview 9

Psoriasis – Therapeutics Development 10

Psoriasis – Therapeutics Assessment 42

Psoriasis – Companies Involved in Therapeutics Development 58

Psoriasis – Drug Profiles 127

Psoriasis – Dormant Projects 660

Psoriasis – Discontinued Products 681

Psoriasis – Product Development Milestones 685

Appendix 696

List of Tables

List of Tables

Number of Products under Development for Psoriasis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Psoriasis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..9), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..10), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Products under Development by Companies, H2 2018 (Contd..9), H2 2018

Products under Development by Companies, H2 2018 (Contd..10), H2 2018

Products under Development by Companies, H2 2018 (Contd..11), H2 2018

Products under Development by Companies, H2 2018 (Contd..12), H2 2018

Products under Development by Companies, H2 2018 (Contd..13), H2 2018

Products under Development by Companies, H2 2018 (Contd..14), H2 2018

Products under Development by Companies, H2 2018 (Contd..15), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..4), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..4), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Psoriasis – Pipeline by 3SBio Inc, H2 2018

Psoriasis – Pipeline by AbbVie Inc, H2 2018

Psoriasis – Pipeline by Abeome Corp, H2 2018

Psoriasis – Pipeline by AbGenomics International Inc, H2 2018

Psoriasis – Pipeline by Aclaris Therapeutics Inc, H2 2018

Psoriasis – Pipeline by Adello Biologics LLC, H2 2018

Psoriasis – Pipeline by Affibody AB, H2 2018

Psoriasis – Pipeline by Alfacyte Ltd, H2 2018

Psoriasis – Pipeline by Allergan Plc, H2 2018

Psoriasis – Pipeline by Almirall SA, H2 2018

Psoriasis – Pipeline by Alteogen Inc, H2 2018

Psoriasis – Pipeline by Alvotech Iceland, H2 2018

Psoriasis – Pipeline by Amgen Inc, H2 2018

Psoriasis – Pipeline by AnaptysBio Inc, H2 2018

Psoriasis – Pipeline by ApoPharma Inc, H2 2018

Psoriasis – Pipeline by Aptevo Therapeutics Inc, H2 2018

Psoriasis – Pipeline by Arbor Pharmaceuticals LLC, H2 2018

Psoriasis – Pipeline by Arrien Pharmaceuticals LLC, H2 2018

Psoriasis – Pipeline by AstraZeneca Plc, H2 2018

Psoriasis – Pipeline by Athenex Inc, H2 2018

Psoriasis – Pipeline by Atlantic Bio Sci LLC, H2 2018

Psoriasis – Pipeline by Aurigene Discovery Technologies Ltd, H2 2018

Psoriasis – Pipeline by Baliopharm AG, H2 2018

Psoriasis – Pipeline by Bausch Health Companies Inc, H2 2018

Psoriasis – Pipeline by Bayer AG, H2 2018

Psoriasis – Pipeline by Beta Pharma Inc, H2 2018

Psoriasis – Pipeline by BioApex sro, H2 2018

Psoriasis – Pipeline by Biocad, H2 2018

Psoriasis – Pipeline by Biocon Ltd, H2 2018

Psoriasis – Pipeline by BioLingus AG, H2 2018

Psoriasis – Pipeline by Bionovis SA, H2 2018

Psoriasis – Pipeline by BirchBioMed Inc, H2 2018

Psoriasis – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Psoriasis – Pipeline by Boston Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Brickell Biotech Inc, H2 2018

Psoriasis – Pipeline by Bristol-Myers Squibb Co, H2 2018

Psoriasis – Pipeline by C4X Discovery Holdings PLC, H2 2018

Psoriasis – Pipeline by CalciMedica Inc, H2 2018

Psoriasis – Pipeline by Can-Fite BioPharma Ltd, H2 2018

Psoriasis – Pipeline by Celgene Corp, H2 2018

Psoriasis – Pipeline by Celon Pharma SA, H2 2018

Psoriasis – Pipeline by ChemoCentryx Inc, H2 2018

Psoriasis – Pipeline by ChironWells GmbH, H2 2018

Psoriasis – Pipeline by Coherus BioSciences Inc, H2 2018

Psoriasis – Pipeline by Compugen Ltd, H2 2018

Psoriasis – Pipeline by Concenter BioPharma Silkim Ltd, H2 2018

Psoriasis – Pipeline by Crescita Therapeutics Inc, H2 2018

Psoriasis – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Psoriasis – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2018

Psoriasis – Pipeline by DURECT Corp, H2 2018

Psoriasis – Pipeline by Eli Lilly and Co, H2 2018

Psoriasis – Pipeline by ELORAC Inc, H2 2018

Psoriasis – Pipeline by Escalier Biosciences BV, H2 2018

Psoriasis – Pipeline by Evelo Biosciences Inc, H2 2018

Psoriasis – Pipeline by Exicure Inc, H2 2018

Psoriasis – Pipeline by Fresenius SE & Co KGaA, H2 2018

Psoriasis – Pipeline by FunPep Co Ltd, H2 2018

Psoriasis – Pipeline by FYB202 GmbH & Co KG, H2 2018

Psoriasis – Pipeline by Galapagos NV, H2 2018

Psoriasis – Pipeline by Galderma SA, H2 2018

Psoriasis – Pipeline by Galectin Therapeutics Inc, H2 2018

Psoriasis – Pipeline by Genentech Inc, H2 2018

Psoriasis – Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Psoriasis – Pipeline by Genfit SA, H2 2018

Psoriasis – Pipeline by Genor BioPharma Co Ltd, H2 2018

Psoriasis – Pipeline by GlaxoSmithKline Plc, H2 2018

Psoriasis – Pipeline by GlycoMar Ltd, H2 2018

Psoriasis – Pipeline by Grunenthal GmbH, H2 2018

Psoriasis – Pipeline by Helix BioMedix Inc, H2 2018

Psoriasis – Pipeline by HitGen LTD, H2 2018

Psoriasis – Pipeline by Huabo Biopharm Co Ltd, H2 2018

Psoriasis – Pipeline by Hualan Biological Engineering Inc, H2 2018

Psoriasis – Pipeline by Hydra Biosciences Inc, H2 2018

Psoriasis – Pipeline by iCo Therapeutics Inc, H2 2018

Psoriasis – Pipeline by Immune Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Immungenetics AG, H2 2018

Psoriasis – Pipeline by Immunwork Inc, H2 2018

Psoriasis – Pipeline by Innovation Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Inspyr Therapeutics Inc, H2 2018

Psoriasis – Pipeline by Instituto Biomar SA, H2 2018

Psoriasis – Pipeline by Istesso Ltd, H2 2018

Psoriasis – Pipeline by Japan Tobacco Inc, H2 2018

Psoriasis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018

Psoriasis – Pipeline by Johnson & Johnson, H2 2018

Psoriasis – Pipeline by Kadmon Corp LLC, H2 2018

Psoriasis – Pipeline by Kaken Pharmaceutical Co Ltd, H2 2018

Psoriasis – Pipeline by Kang Stem Biotech Co Ltd, H2 2018

Psoriasis – Pipeline by Kv1.3 Therapeutics, H2 2018

Psoriasis – Pipeline by Kymab Ltd, H2 2018

Psoriasis – Pipeline by Lead Pharma Holding BV, H2 2018

Psoriasis – Pipeline by LEO Pharma A/S, H2 2018

Psoriasis – Pipeline by Link Health Group, H2 2018

Psoriasis – Pipeline by Lupin Ltd, H2 2018

Psoriasis – Pipeline by Lycera Corp, H2 2018

Psoriasis – Pipeline by mAbxience SA, H2 2018

Psoriasis – Pipeline by Maruho Co Ltd, H2 2018

Psoriasis – Pipeline by Merck KGaA, H2 2018

Psoriasis – Pipeline by Metrion Biosciences Ltd, H2 2018

Psoriasis – Pipeline by MetrioPharm AG, H2 2018

Psoriasis – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Psoriasis – Pipeline by Momenta Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Mycenax Biotech Inc, H2 2018

Psoriasis – Pipeline by Nanology LLC, H2 2018

Psoriasis – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2018

Psoriasis – Pipeline by Nimbus Therapeutics LLC, H2 2018

Psoriasis – Pipeline by Nordic Group BV, H2 2018

Psoriasis – Pipeline by NovaLead Pharma Pvt Ltd, H2 2018

Psoriasis – Pipeline by Novan Inc, H2 2018

Psoriasis – Pipeline by Novartis AG, H2 2018

Psoriasis – Pipeline by Nuevolution AB, H2 2018

Psoriasis – Pipeline by Numab Innovation AG, H2 2018

Psoriasis – Pipeline by Oncobiologics Inc, H2 2018

Psoriasis – Pipeline by Orphagen Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Pfizer Inc, H2 2018

Psoriasis – Pipeline by Pharmedartis GmbH, H2 2018

Psoriasis – Pipeline by Phenex Pharmaceuticals AG, H2 2018

Psoriasis – Pipeline by Philogen SpA, H2 2018

Psoriasis – Pipeline by PinCell srl, H2 2018

Psoriasis – Pipeline by Pivot Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Plant Advanced Technologies SA, H2 2018

Psoriasis – Pipeline by Principia Biopharma Inc, H2 2018

Psoriasis – Pipeline by Provectus Biopharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Qilu Pharmaceutical Co Ltd, H2 2018

Psoriasis – Pipeline by Realm Therapeutics Plc, H2 2018

Psoriasis – Pipeline by Reata Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by RedHill Biopharma Ltd, H2 2018

Psoriasis – Pipeline by Reliance Life Sciences Pvt Ltd, H2 2018

Psoriasis – Pipeline by Samumed LLC, H2 2018

Psoriasis – Pipeline by Sandoz International GmbH, H2 2018

Psoriasis – Pipeline by Sareum Holdings Plc, H2 2018

Psoriasis – Pipeline by SBI Biotech Co Ltd, H2 2018

Psoriasis – Pipeline by selectION Inc, H2 2018

Psoriasis – Pipeline by Shanghai Henlius Biotech Co Ltd, H2 2018

Psoriasis – Pipeline by Shulov Innovative Science Ltd, H2 2018

Psoriasis – Pipeline by Sienna Biopharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Soligenix Inc, H2 2018

Psoriasis – Pipeline by Spherium Biomed SL, H2 2018

Psoriasis – Pipeline by sterna biologicals Gmbh & Co KG, H2 2018

Psoriasis – Pipeline by Sublimity Therapeutics Ltd, H2 2018

Psoriasis – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Psoriasis – Pipeline by Syntrix Biosystems Inc, H2 2018

Psoriasis – Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2018

Psoriasis – Pipeline by TheraMAB LLC, H2 2018

Psoriasis – Pipeline by Tolero Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by Torrent Pharmaceuticals Ltd, H2 2018

Psoriasis – Pipeline by UCB SA, H2 2018

Psoriasis – Pipeline by Vicore Pharma AB, H2 2018

Psoriasis – Pipeline by Visionary Pharmaceuticals Inc, H2 2018

Psoriasis – Pipeline by vTv Therapeutics Inc, H2 2018

Psoriasis – Pipeline by Wellstat Therapeutics Corp, H2 2018

Psoriasis – Pipeline by XBiotech Inc, H2 2018

Psoriasis – Pipeline by Yuhan Corp, H2 2018

Psoriasis – Pipeline by Zai Lab Ltd, H2 2018

Psoriasis – Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2018

Psoriasis – Dormant Projects, H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..1), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..2), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..3), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..4), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..5), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..6), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..7), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..8), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..9), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..10), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..11), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..12), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..13), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..14), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..15), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..16), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..17), H2 2018

Psoriasis – Dormant Projects, H2 2018 (Contd..18), H2 2018

Psoriasis – Discontinued Products, H2 2018

Psoriasis – Discontinued Products, H2 2018 (Contd..1), H2 2018

Psoriasis – Discontinued Products, H2 2018 (Contd..2), H2 2018

Psoriasis – Discontinued Products, H2 2018 (Contd..3), H2 2018

List of Figures

List of Figures

Number of Products under Development for Psoriasis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Psoriasis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports